Clinical Trials

Nasopharyngeal Carcinoma

NCT07546383 2026-04-22

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase NA Recruiting

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03389477 2026-04-21

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

26 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT03485209 2026-04-20

innovaTV 207

GastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04389632 2026-04-20

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01810913 2026-04-17

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04671667 2026-04-17

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

188 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05172245 2026-04-17

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

46 enrolled

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06064097 2026-04-17

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

50 enrolled

Nasopharyngeal Carcinoma

NCT06477692 2026-04-17

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

80 enrolled

Head and Neck Neoplasms

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

120 enrolled

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT06702033 2026-04-16

MINT-2

142 enrolled

Oropharyngeal Neoplasms

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

50 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT07528495 2026-04-14

Eliminate

Phase 2/3 Recruiting

396 enrolled

Head and Neck Neoplasms

NCT03323463 2026-04-13

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

316 enrolled

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03811015 2026-04-13

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Phase 2/3 Active not recruiting

Oropharyngeal Neoplasms

NCT03952585 2026-04-13

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

384 enrolled 22 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT04620187 2026-04-13

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

37 enrolled

Phase 2/3 Active not recruiting

Salivary Gland Neoplasms

NCT05063552 2026-04-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

430 enrolled

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05075980 2026-04-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

174 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT06029270 2026-04-13

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Nasopharyngeal Carcinoma

NCT07195734 2026-04-13

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

180 enrolled

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07219212 2026-04-13

LUMIRAY

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07276399 2026-04-13

OrigAMI-5

500 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07325539 2026-04-13

LIGHT

55 enrolled

Nasopharyngeal Carcinoma

NCT07423078 2026-04-13

WOLF

87 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07524413 2026-04-13

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

514 enrolled

Nasopharyngeal Neoplasms

NCT02819752 2026-04-09

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05563480 2026-04-07

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

47 enrolled

Nasopharyngeal Carcinoma

NCT06457503 2026-04-06

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Phase 2/3 Active not recruiting

Nasopharyngeal Neoplasms

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05050162 2026-04-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT06532279 2026-04-03

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

98 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT01898494 2026-04-01

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

519 enrolled 16 charts

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT06236425 2026-04-01

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

7 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06223568 2026-03-27

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

70 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT07497607 2026-03-27

REDUCE-30

31 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03410615 2026-03-24

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

129 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06323460 2026-03-24

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT06535607 2026-03-24

eVOLVE-02

GastrointestinalGynecologicHead & Neck

257 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT02734537 2026-03-23

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

189 enrolled

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

14 enrolled

Head and Neck Neoplasms

NCT07125755 2026-03-23

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

386 enrolled

Squamous Cell Cancer of Head and Neck (SCCHN)

NCT04883281 2026-03-18

DARTBOARD

Phase 2 Completed

50 enrolled

Head and Neck Neoplasms

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled